Evidence map›Paper›PMID 24489090›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2014

IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis.

Lauren M F Merlo, Elizabeth Pigott, James B DuHadaway, Samantha Grabler, Richard Metz, George C Prendergast, Laura Mandik-Nayak

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 118 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Investigation of the Impact of Tryptophan-Metabolizing Enzymes and Kynurenic Acid on Antibody-Mediated Glomerulonephritis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Metabolites as drivers and targets in rheumatoid arthritis.Clinical and experimental immunology · 2022
    Article
  17. Review
  18. Article
  19. Article
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lauren M F Merlo *Lankenau Institute for Medical Research, Wynnewood PA USA.
Elizabeth Pigott *Lankenau Institute for Medical Research, Wynnewood PA USA.
James B DuHadawayLankenau Institute for Medical Research, Wynnewood PA USA.
Samantha GrablerLankenau Institute for Medical Research, Wynnewood PA USA.
Richard MetzNew Link Genetics Corporation, Ames IA USA.
George C PrendergastLankenau Institute for Medical Research, Wynnewood PA USA.
Laura Mandik-NayakLankenau Institute for Medical Research, Wynnewood PA USA.
Lankenau Institute for Medical Research · USNewLink Genetics (United States) · US

Funding

IDO Inhibitors for Combinatorial Cancer TherapyR01CA109542 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI PRENDERGAST, GEORGE C · 2005 to 2015
$2.0M
IDO Pathways in Inflammatory Pathogenesis and Treatment of Rheumatoid ArthritisR01AR057847 · NIAMS · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI MANDIK-NAYAK, LAURA · 2010 to 2014
$1.8M
NCI NIH HHS R01 CA109542NIAMS NIH HHS 5-R01 AR057847NIAMS NIH HHS R01 AR057847
6 · The paper itself

Abstract

Rheumatoid arthritis and other autoimmune disorders are associated with altered activity of the immunomodulatory enzyme IDO. However, the precise contributions of IDO function to autoimmunity remain unclear. In this article, we examine the effect of two different IDO enzymes, IDO1 and IDO2, on the development of autoimmune arthritis in the KRN preclinical model of rheumatoid arthritis. We find that IDO2, not IDO1, is critical for arthritis development, providing direct evidence of separate in vivo functions for IDO1 and IDO2. Mice null for Ido2 display decreased joint inflammation relative to wild-type mice owing to a reduction in pathogenic autoantibodies and Ab-secreting cells. Notably, IDO2 appears to specifically mediate autoreactive responses, but not normal B cell responses, as total serum Ig levels are not altered and IDO2 knockout mice are able to mount productive Ab responses to model Ags in vitro and in vivo. Reciprocal adoptive transfer studies confirm that autoantibody production and arthritis are modulated by IDO2 expression in a cell type extrinsic to the T cell. Taken together, our results, provide important insights into IDO2 function by defining its pathogenic contributions to autoantibody-mediated autoimmunity.

Indexed as

Antibody FormationAnimalsArthritis, ExperimentalArthritis, RheumatoidAutoantibodiesB-LymphocytesGene Expression Regulation, EnzymologicIndoleamine-Pyrrole 2,3,-DioxygenaseMiceMice, KnockoutT-LymphocytesAutoantibodiesIDO1 protein, mouseIDO2 protein, mouseIndoleamine-Pyrrole 2,3,-Dioxygenase

Identifiers

PMID24489090
PMCPMC3947779
OpenAlexW2145440737

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.